Ottawa Hospital Research Institute

Dr. Marc Carrier, MD

Claim this profile

The Ottawa Hospital

Studies Deep Vein Thrombosis
Studies Venous Thromboembolism
7 reported clinical trials
9 drugs studied

Affiliated Hospitals

Image of trial facility.

The Ottawa Hospital

Clinical Trials Marc Carrier, MD is currently running

Image of trial facility.

Anticoagulation Strategies

for Blood Clots in Cancer Patients

Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts. The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 2 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 30 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy for these patients.

Recruiting

5 awards

Phase 4

4 criteria

Image of trial facility.

Surveillance vs. Rivaroxaban

for Pulmonary Embolism

The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents "true" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.

Recruiting

2 awards

Phase 4

3 criteria

More about Marc Carrier, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Marc Carrier, MD has experience with

  • Rivaroxaban
  • Dalteparin
  • Enoxaparin
  • Tinzaparin
  • Placebo
  • Limited Cancer Screening

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Marc Carrier, MD specialize in?

Is Marc Carrier, MD currently recruiting for clinical trials?

Are there any treatments that Marc Carrier, MD has studied deeply?

What is the best way to schedule an appointment with Marc Carrier, MD?

What is the office address of Marc Carrier, MD?

Is there any support for travel costs?